8229 Boone Boulevard
About CEL-SCI Corporation
402 articles with CEL-SCI Corporation
CEL-SCI Selected by National Institutes of Health to Showcase Its LEAPS Technology at BIO International Convention
Platform therapeutic vaccine technology to be showcased at NIH’s Innovation Zone
CEL-SCI’s Scientific Article on Vaccines for Autoimmune Disease Published in Journal of Clinical & Cellular Immunology
LEAPS therapeutic vaccine platform holds potential for early treatment of autoimmune diseases including rheumatoid arthritis, multiple sclerosis and type 1 diabetes
CEL-SCI Corporation reported financial results for the quarter ended December 31, 2018.
Geert Kersten, Chief Executive Officer, will be presenting at the 2019 BIO CEO & Investor Conference in New York, NY on Monday, February 11, 2018 at 2:00 p.m.
CEL-SCI’s LEAPS inventions relate to methods for diagnosing, preventing, and treating disease by generating or modulating the immune response through the use of specific peptides
The Company is now considered in full compliance with the continued listing requirements.
CEL-SCI Corporation reported financial results for the fiscal year ended September 30, 2018
CEL-SCI Corporation is advising the holders of its publicly traded warrants (NYSE American: CVM WS) that the warrants will expire and not be exercisable after 5:00 p.m., New York City time, on October 11, 2018.
CEL-SCI Corporation announced today that the National Institutes of Health (NIH) selected CEL-SCI and its LEAPS* rheumatoid arthritis vaccine candidate as a Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) Commercialization Accelerator Program Phase II awardee for 2018-2019.
The following letter was sent by CEL-SCI Corporation to its shareholders for the upcoming annual meeting
CEL-SCI Corporation announces that the NYSE American (the “Exchange”) has accepted the Company’s plan to bring itself into compliance with the Exchange's continued listing standards.
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study
CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data.
CEL-SCI Corporation reported financial results for the quarter ended June 30, 2018. The Company also reported key clinical and corporate developments achieved during the quarter.
CEL-SCI Corporation reported on a communication received today from the staff of the NYSE American, its current listing exchange, that it considered the Company to be noncompliant with certain listing requirements based on its quarterly report for the period ended March 31, 2018.
CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering and Concurrent Private Placement
CEL-SCI Corporation announced that it has closed its previously announced registered direct offering and concurrent private placement with institutional investors.
Cel-Sci Wins Breach of Contract Ruling against Clinical Research Organization inVentiv, Now Known as Syneos Health
CEL-SCI Corporation (NYSE American: CVM) announced today that after a four and a half year battle a decision has been delivered by the arbitrator in CEL-SCI's arbitration suit against clinical development giant inVentiv.
CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.
New LEAPS Patents aimed at Multiple Infectious Diseases
CEL-SCI Corporation announced that Geert Kersten, Chief Executive Officer, will be presenting today, June 5, 2018 at 12:00 pm PT / 3:00 pm ET at the 8th annual LD Micro Invitational.
CEL-SCI Corporation wants to remind its shareholders that the lower exercise price for its outstanding Series S warrants.